170 related articles for article (PubMed ID: 27377482)
1. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.
Fens MH; Cabrales P; Scicinski J; Larkin SK; Suh JH; Kuypers FA; Oronsky N; Lybeck M; Oronsky A; Oronsky B
Med Oncol; 2016 Aug; 33(8):85. PubMed ID: 27377482
[TBL] [Abstract][Full Text] [Related]
2. Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001.
Cirrik S; Ugurel E; Aksu AC; Oronsky B; Cabrales P; Yalcin O
Biorheology; 2019; 56(4):221-235. PubMed ID: 31640080
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.
Oronsky B; Oronsky N; Cabrales P
J Cell Mol Med; 2018 Oct; 22(10):5076-5082. PubMed ID: 30010241
[TBL] [Abstract][Full Text] [Related]
4. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
[TBL] [Abstract][Full Text] [Related]
5. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.
Scicinski J; Oronsky B; Ning S; Knox S; Peehl D; Kim MM; Langecker P; Fanger G
Redox Biol; 2015 Dec; 6():1-8. PubMed ID: 26164533
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
Zhao H; Ning S; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Oncotarget; 2015 Dec; 6(41):43172-81. PubMed ID: 26657731
[TBL] [Abstract][Full Text] [Related]
7. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
Cabrales P; Scicinski J; Reid T; Kuypers F; Larkin S; Fens M; Oronsky A; Oronsky B
Med Oncol; 2016 Jul; 33(7):63. PubMed ID: 27229330
[TBL] [Abstract][Full Text] [Related]
8. Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration.
Shiva S; Huang Z; Grubina R; Sun J; Ringwood LA; MacArthur PH; Xu X; Murphy E; Darley-Usmar VM; Gladwin MT
Circ Res; 2007 Mar; 100(5):654-61. PubMed ID: 17293481
[TBL] [Abstract][Full Text] [Related]
9. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
Oronsky B; Scicinski J; Cabrales P; Minchinton A
Clin Epigenetics; 2016; 8():53. PubMed ID: 27175220
[TBL] [Abstract][Full Text] [Related]
10. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332
[TBL] [Abstract][Full Text] [Related]
11. The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.
Cabrales P; Caroen S; Oronsky A; Carter C; Trepel J; Summers T; Reid T; Oronsky N; Lybeck M; Oronsky B
Expert Rev Hematol; 2017 Jun; 10(6):575-582. PubMed ID: 28448172
[TBL] [Abstract][Full Text] [Related]
12. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.
Oronsky B; Scicinski J; Reid T; Oronsky A; Carter C; Oronsky N; Cabrales P
Discov Med; 2016 Apr; 21(116):251-65. PubMed ID: 27232511
[TBL] [Abstract][Full Text] [Related]
13. RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature.
Jani VP; Asaro R; Oronsky B; Cabrales P
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946824
[TBL] [Abstract][Full Text] [Related]
14. RRx-001 protects against cisplatin-induced toxicities.
Oronsky B; Reid TR; Larson C; Carter CA; Brzezniak CE; Oronsky A; Cabrales P
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1671-1677. PubMed ID: 28417195
[TBL] [Abstract][Full Text] [Related]
15. Hemoglobin oxygen fractional saturation regulates nitrite-dependent vasodilation of aortic ring bioassays.
Isbell TS; Gladwin MT; Patel RP
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2565-72. PubMed ID: 17766472
[TBL] [Abstract][Full Text] [Related]
16. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition.
Oronsky B; Scribner C; Aggarwal R; Cabrales P
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2045-2050. PubMed ID: 31250159
[TBL] [Abstract][Full Text] [Related]
17. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation.
Cosby K; Partovi KS; Crawford JH; Patel RP; Reiter CD; Martyr S; Yang BK; Waclawiw MA; Zalos G; Xu X; Huang KT; Shields H; Kim-Shapiro DB; Schechter AN; Cannon RO; Gladwin MT
Nat Med; 2003 Dec; 9(12):1498-505. PubMed ID: 14595407
[TBL] [Abstract][Full Text] [Related]
18. Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity.
Zhang Z; Naughton D; Winyard PG; Benjamin N; Blake DR; Symons MC
Biochem Biophys Res Commun; 1998 Aug; 249(3):767-72. PubMed ID: 9731211
[TBL] [Abstract][Full Text] [Related]
19. Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.
Huang Z; Fu J; Zhang Y
J Med Chem; 2017 Sep; 60(18):7617-7635. PubMed ID: 28505442
[TBL] [Abstract][Full Text] [Related]
20. The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
Scicinski J; Fisher G; Carter C; Cho-Phan C; Kunz P; Ning S; Knox S; Oronsky B; Caroen S; Parker C; Fanger G; Reid T
Redox Biol; 2015 Aug; 5():422. PubMed ID: 28162292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
